2023
Polysomnographic predictors of incident diabetes and pre-diabetes: an analysis of the DREAM study.
Wojeck B, Inzucchi S, Qin L, Yaggi H. Polysomnographic predictors of incident diabetes and pre-diabetes: an analysis of the DREAM study. Journal Of Clinical Sleep Medicine 2023, 19: 703-710. PMID: 36689314, PMCID: PMC10071389, DOI: 10.5664/jcsm.10414.Peer-Reviewed Original ResearchConceptsApnea-hypopnea indexBody mass indexIncident diabetesPolysomnographic predictorsMass indexOxygen saturationMean nocturnal oxygen saturationObstructive sleep apnea (OSA) evaluationObstructive sleep apnea populationEpworth Sleepiness Scale scoreSleep apnea populationGlucose-lowering medicationsNocturnal oxygen saturationSleep-disordered breathingIncidence of diabetesPeriodic limb movementsLaboratory-based polysomnographyCheyne-Stokes respirationSleep apnea severitySleep apnea evaluationIncident prediabetesOxygen desaturationCentral apneaHemoglobin A1cPrimary outcome
2020
The Impact of Empagliflozin on Obstructive Sleep Apnea, Cardiovascular, and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial
Neeland IJ, Eliasson B, Kasai T, Marx N, Zinman B, Inzucchi SE, Wanner C, Zwiener I, Wojeck BS, Yaggi HK, Johansen OE. The Impact of Empagliflozin on Obstructive Sleep Apnea, Cardiovascular, and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020, 43: 3007-3015. PMID: 33004464, PMCID: PMC7770278, DOI: 10.2337/dc20-1096.Peer-Reviewed Original ResearchConceptsObstructive sleep apneaRenal outcomesOSA statusSleep apneaNew-onset obstructive sleep apneaMultivariable-adjusted Cox regression modelsBaseline obstructive sleep apneaMajor adverse CV eventsEMPA-REG OUTCOME trialEMPA-REG OUTCOMEImpact of empagliflozinPlacebo-adjusted reductionsAdverse CV eventsEffect of empagliflozinHeart failure hospitalizationSystolic blood pressureCox regression modelStandard of careCV deathCV eventsCV outcomesEmpagliflozin treatmentEMPA-REGRenal eventsCV disease